biostudies-literatureMunteanu MMedical Research CouncilNational Institute for Health Research (NIHR)Seventh Framework Programme877-89https://www.ebi.ac.uk/biostudies/studies/S-EPMC5113673biostudies-literatureUnknown44(8)<h4>Background</h4>Blood tests of liver injury are less well validated in non-alcoholic fatty liver disease (NAFLD) than in patients with chronic viral hepatitis.<h4>Aims</h4>To improve the validation of three blood tests used in NAFLD patients, FibroTest for fibrosis staging, SteatoTest for steatosis grading and ActiTest for inflammation activity grading.<h4>Methods</h4>We pre-included new NAFLD patients with biopsy and blood tests from a single-centre cohort (FibroFrance) and from the multicentre FLIP consortium. Contemporaneous biopsies were blindly assessed using the new steatosis, activity and fibrosis (SAF) score, which provides a reliable and reproducible diagnosis and grading/staging of the three elementary features of NAFLD (steatosis, inflammatory activity) and fibrosis with reduAlimentary pharmacology & therapeuticsDiagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference.PMC5113673FP7/2007‐2013CL-2013-01-002HEALTH‐F2‐2009‐241762MC_UU_12013/5Sorensen TPerlemuter GMercadier AGouw ASBellentani SCastille JMFLIP Consortium and the FibroFrance GroupBruckert EMunteanu MRosmorduc OVarsat BMarra FSchirmacher PNgo YDeckmyn OZiol MHartemann AMontani MDe Minicis SDavid EPerazzo HLosi LWendum DRomero Gomez MCabibi DTrauner MGiral PTraussnig SBismuth FIPareja MJThabut DTiniakos DLawlor DBugianesi ERatziu VMoussalli JDufour JFWrba FPoynard TLangon TLebray PMarchesini GBurt ADAnstee QNaveau SRudler MBedossa PLackner CJacqueminet SBrain JTribelli CDay CBury YTerracciano LOliveira CCharlotte FCalmus YfalseDiagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference.<h4>Background</h4>Blood tests of liver injury are less well validated in non-alcoholic fatty liver disease (NAFLD) than in patients with chronic viral hepatitis.<h4>Aims</h4>To improve the validation of three blood tests used in NAFLD patients, FibroTest for fibrosis staging, SteatoTest for steatosis grading and ActiTest for inflammation activity grading.<h4>Methods</h4>We pre-included new NAFLD patients with biopsy and blood tests from a single-centre cohort (FibroFrance) and from the multicentre FLIP consortium. Contemporaneous biopsies were blindly assessed using the new steatosis, activity and fibrosis (SAF) score, which provides a reliable and reproducible diagnosis and grading/staging of the three elementary features of NAFLD (steatosis, inflammatory activity) and fibrosis with redu2016-01-01T00:00:00Z2016 Oct2026-05-29T20:29:55.143Z2019-03-27T02:29:12ZS-EPMC51136732754924410.1111/apt.13770